Related Experiment Videos
Lack of p16/CDKN2 alterations in thyroid carcinomas
K Yane1, N Konishi, Y Kitahori
1Department of Otorhinolaryngology, Nara Medical University, Kashihara, Japan.
Abstract:
Exons 1-3 of the p16/CDKN2 gene and exons 4-9 of the p53 gene were screened for mutations by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of PCR-amplified DNA from human primary thyroid carcinomas and thyroid carcinoma cell lines. The samples included 21 papillary carcinomas, 2 undifferentiated carcinomas, 1 follicular carcinoma, 1 medullary carcinoma and 2 cell lines originating from thyroid undifferentiated carcinomas. No homozygous deletions and mutations in the p16/CDKN2 were observed in any of the primary tumors or cell lined. In contrast, one of the two undifferentiated carcinomas an both cell lines demonstrated point mutations in the p53 gene. These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma.
Insights
Mutations in the p16/CDKN2 gene are not essential for thyroid cancer development. However, alterations in the p53 gene may contribute to the progression of differentiated thyroid tumors into undifferentiated carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Thyroid carcinomas are heterogeneous malignancies.
- Understanding the genetic alterations driving thyroid cancer progression is crucial for targeted therapies.
Purpose of the Study:
- To investigate mutations in the p16/CDKN2 and p53 tumor suppressor genes in various human thyroid carcinoma types.
- To determine the role of these genes in thyroid cancer development and progression.
Main Methods:
- Screening of p16/CDKN2 (exons 1-3) and p53 (exons 4-9) genes using single-strand conformation polymorphism (SSCP) analysis.
- Direct sequencing of PCR-amplified DNA from 21 papillary, 2 undifferentiated, 1 follicular, 1 medullary thyroid carcinomas, and 2 undifferentiated carcinoma cell lines.
Main Results:
- No mutations or homozygous deletions were found in the p16/CDKN2 gene in any samples.
- Point mutations in the p53 gene were identified in one undifferentiated carcinoma and both cell lines.
Conclusions:
- p16/CDKN2 gene alterations are not a prerequisite for thyroid malignant transformation.
- p53 gene mutations appear to be involved in the transition from differentiated to undifferentiated thyroid carcinoma.